Collectively, our findings highlight the importance of COL11A1 in EOC tumour progression and chemoresistance, and suggest that future therapies targeting COL11A1 or the Akt signalling pathway [38] might provide new opportunities for therapeutic intervention in chemoresistant EOC. This evidence concerns the gene AKT1 and neoplasm.